Flagship Pioneering has committed an initial £100 million to establish a London unit creating AI-native platform companies, taking its company-creation model beyond Cambridge, Massachusetts, for the first time.
The new Flagship Origination Lab, U.K., will be part of Flagship Labs and focus on companies working in human and planetary health and other scientific and technology fields. The company expects to recruit and train a first U.K. group of about 50, including scientist-entrepreneurs and operators.
Flagship expects partnerships to attract a further £500 million, but did not identify prospective partners or give a timetable for raising it. Bloomberg Law reported that the initial £100 million is expected to be deployed over the next few years; Flagship’s announcement did not provide a spending schedule.
The lab builds on Flagship’s presence in Britain. The company opened a London office in 2023 and signed a memorandum of understanding with the U.K. government. The government described London as Flagship’s first base outside the United States; the new lab is its first dedicated company-creation unit outside the country.
Flagship points to work in the U.K. over the past three years, including clinical trials by its founded companies such as Generate:Biomedicines and partnerships across academic, data and regulatory fields.
Flagship says Moderna is among more than 130 companies it has created over a history spanning more than 25 years. It cites the U.K.’s clinical-trial infrastructure, genomics and health-data resources, regulation, and scientific and entrepreneurial talent as reasons for the expansion. The company has not announced the lab’s first companies or a launch date.



